YUCAIPA, Calif.--(BUSINESS WIRE)--Ingen Technologies, Inc. (ITEC), manufacturer of various types of gas flow meters, announced today that in a recent NEWSUSA® article Ingen’s Oxyview® flow meter, developed to help lung patients, is now ready to help car engines.
The Oxyview® flow meter was developed to help patients afflicted with COPD, a market that exceeds $10 billion. In the meanwhile, the potential $100 billion market that is now unfolding can rapidly change the dynamics of this emerging manufacturer.
“The use of flow meters in automotive engines that use Electronic Fuel Injection Enhancers (EFIE) is increasing. EFIE will unleash the full potential of the fuel saver and can save 5%-10% on fuel costs simply by 'leaning' the fuel mixture”, said Chairman/CEO Scott Sands. “This is an extraordinary opportunity for our company and for our shareholders who will enjoy the fruits of our rapid growth”.
The Oxyview® flow meter has been tested by FuelSaver-MPG, Inc., and works well as a complement to their EFIE and HHO boosters. According to some of the automotive EFIE manufacturers, there is no product equivalent to Ingen’s Oxyview® flow meter. In the U.S., this market is approximately 10% of the vehicles on-the-road, or approximately 10 million vehicles. Worldwide, the market is $100M.
“The potential sales of Ingen’s flow meter for the EFIE market could be as substantial as $70M. With the current economic situation and bouncing oil prices, it would be expected that the EFIE market would increase and cause even greater sales of Oxyview®,” stated Thomas J. Neavitt, CFO.
About Ingen Technologies, Inc.
Ingen is an emerging public company (Pink Sheets:ITEC), registered and licensed by the FDA/DHS. The company introduced Oxyview® into the respiratory market in 2007; the world’s first in-line oxygen flow meter. The company has expanded the distribution of its flow meters to other industries thus increasing the potential for wide sources of revenue.
According to the 2002 CDC Report, there are approximately 32 million people living in the United States that suffer from Chronic Obstructive Pulmonary Disease, more commonly known as “COPD”. COPD is the major cause of hospitalizations and the fifth leading cause of death in the United States. A large portion of the COPD patients receive oxygen therapy. Ingen Technologies owns the patents and trademarks for Oxyview® and OxyAlert®, and there are no other products that compete or simulate either of these two products within the medical industry. For more information visit www.ingen-tech.com.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.
The Oxyview® flow meter was developed to help patients afflicted with COPD, a market that exceeds $10 billion. In the meanwhile, the potential $100 billion market that is now unfolding can rapidly change the dynamics of this emerging manufacturer.
“The use of flow meters in automotive engines that use Electronic Fuel Injection Enhancers (EFIE) is increasing. EFIE will unleash the full potential of the fuel saver and can save 5%-10% on fuel costs simply by 'leaning' the fuel mixture”, said Chairman/CEO Scott Sands. “This is an extraordinary opportunity for our company and for our shareholders who will enjoy the fruits of our rapid growth”.
The Oxyview® flow meter has been tested by FuelSaver-MPG, Inc., and works well as a complement to their EFIE and HHO boosters. According to some of the automotive EFIE manufacturers, there is no product equivalent to Ingen’s Oxyview® flow meter. In the U.S., this market is approximately 10% of the vehicles on-the-road, or approximately 10 million vehicles. Worldwide, the market is $100M.
“The potential sales of Ingen’s flow meter for the EFIE market could be as substantial as $70M. With the current economic situation and bouncing oil prices, it would be expected that the EFIE market would increase and cause even greater sales of Oxyview®,” stated Thomas J. Neavitt, CFO.
About Ingen Technologies, Inc.
Ingen is an emerging public company (Pink Sheets:ITEC), registered and licensed by the FDA/DHS. The company introduced Oxyview® into the respiratory market in 2007; the world’s first in-line oxygen flow meter. The company has expanded the distribution of its flow meters to other industries thus increasing the potential for wide sources of revenue.
According to the 2002 CDC Report, there are approximately 32 million people living in the United States that suffer from Chronic Obstructive Pulmonary Disease, more commonly known as “COPD”. COPD is the major cause of hospitalizations and the fifth leading cause of death in the United States. A large portion of the COPD patients receive oxygen therapy. Ingen Technologies owns the patents and trademarks for Oxyview® and OxyAlert®, and there are no other products that compete or simulate either of these two products within the medical industry. For more information visit www.ingen-tech.com.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company’s periodic filings with the U.S. Securities and Exchange Commission.
Source : http://www.businesswire.com/portal/site/google/?ndmViewId=news_view&newsId=20081124005102&newsLang=en
Post a Comment